Trial Profile
Single-center, Double-blind (ACT-246475), Open-label (Clopidogrel, Prasugrel, and Ticagrelor), Placebo-controlled, Randomized, Two-way Crossover Study to Investigate the Pharmacodynamics, Safety, and Tolerability of a Single Oral Dose of Clopidogrel or, Prasugrel, or Ticagrelor When Administered After a Single Subcutaneous Dose of the P2Y12 Antagonist ACT-246475 in Healthy Male and Female Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Selatogrel (Primary) ; Clopidogrel; Prasugrel; Ticagrelor
- Indications Acute coronary syndromes; Cardiovascular disorders; Coronary artery disease
- Focus Pharmacodynamics
- Sponsors Idorsia Pharmaceuticals
- 07 Jan 2021 Results assessing effects of clopidogrel, prasugrel, and ticagrelor loading doses in healthy subjects when administered at different time intervals after selatogrel or placebo, published in the Thrombosis and Haemostasis
- 21 Mar 2020 Results presented at the 121st Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 28 Jun 2019 Status changed from recruiting to completed.